4.0
Jul 23, 2014
Recommend
CEO approval
Business Outlook
Pros
Mostly good people and good perks, particularly in SF. Now that Genentech is part of the Roche group, there is more opportunities worldwide which is a good thing.
Cons
Not necessarily good at getting rid of poor performers. They somehow seem to linger on despite inadequate performance.